Vertex Pharmaceuticals Incorporated (VRTX) CMO Jeffrey Chodakewitz Sells 5,157 Shares

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Jeffrey Chodakewitz sold 5,157 shares of the firm’s stock in a transaction dated Wednesday, June 21st. The stock was sold at an average price of $132.87, for a total value of $685,210.59. Following the completion of the transaction, the chief marketing officer now directly owns 127,668 shares in the company, valued at $16,963,247.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jeffrey Chodakewitz also recently made the following trade(s):

  • On Tuesday, May 2nd, Jeffrey Chodakewitz sold 8,979 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $121.05, for a total value of $1,086,907.95.
  • On Wednesday, April 5th, Jeffrey Chodakewitz sold 8,021 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $114.00, for a total value of $914,394.00.
  • On Monday, April 3rd, Jeffrey Chodakewitz sold 2,291 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $108.85, for a total value of $249,375.35.
  • On Wednesday, March 29th, Jeffrey Chodakewitz sold 13,750 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $106.65, for a total value of $1,466,437.50.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down 1.50% during mid-day trading on Friday, hitting $133.50. The stock had a trading volume of 2,172,643 shares. The firm has a market cap of $33.25 billion, a PE ratio of 186.19 and a beta of 1.65. Vertex Pharmaceuticals Incorporated has a 52-week low of $71.46 and a 52-week high of $137.00. The firm has a 50 day moving average price of $120.67 and a 200 day moving average price of $98.72.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Thursday, April 27th. The pharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.09. The company had revenue of $714.72 million for the quarter, compared to analysts’ expectations of $692.64 million. Vertex Pharmaceuticals had a return on equity of 3.00% and a net margin of 8.64%. The firm’s quarterly revenue was up 79.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.09 EPS. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post $1.66 EPS for the current year.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

COPYRIGHT VIOLATION WARNING: This article was originally posted by sleekmoney and is owned by of sleekmoney. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://sleekmoney.com/vertex-pharmaceuticals-incorporated-vrtx-cmo-jeffrey-chodakewitz-sells-5157-shares/1935843.html.

A number of research analysts have recently weighed in on the company. Needham & Company LLC raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $155.00 price objective on the stock in a research report on Friday. Leerink Swann reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday. Jefferies Group LLC reaffirmed a “buy” rating and set a $126.00 price objective on shares of Vertex Pharmaceuticals in a research report on Friday, June 9th. CIBC raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Friday, June 2nd. Finally, Oppenheimer Holdings, Inc. raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $150.00 target price on the stock in a research note on Friday, June 2nd. Eight analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $118.75.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Vertex Pharmaceuticals by 2,699.4% in the first quarter. BlackRock Inc. now owns 19,246,380 shares of the pharmaceutical company’s stock valued at $2,104,591,000 after buying an additional 18,558,874 shares during the period. Vanguard Group Inc. raised its stake in shares of Vertex Pharmaceuticals by 3.5% in the first quarter. Vanguard Group Inc. now owns 16,474,890 shares of the pharmaceutical company’s stock valued at $1,801,530,000 after buying an additional 560,796 shares during the period. State Street Corp raised its stake in shares of Vertex Pharmaceuticals by 2.0% in the first quarter. State Street Corp now owns 12,013,178 shares of the pharmaceutical company’s stock valued at $1,313,647,000 after buying an additional 239,017 shares during the period. Clearbridge Investments LLC raised its stake in shares of Vertex Pharmaceuticals by 1.2% in the first quarter. Clearbridge Investments LLC now owns 8,754,618 shares of the pharmaceutical company’s stock valued at $957,317,000 after buying an additional 105,260 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Vertex Pharmaceuticals by 8.9% in the first quarter. Geode Capital Management LLC now owns 2,339,821 shares of the pharmaceutical company’s stock valued at $255,483,000 after buying an additional 191,154 shares during the period. 94.18% of the stock is currently owned by institutional investors and hedge funds.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/vertex-pharmaceuticals-incorporated-vrtx-cmo-jeffrey-chodakewitz-sells-5157-shares/1935843.html

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *